title: Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.
abstract: Iron overload used to be considered rare in hemodialysis patients but its clinical frequency is now increasingly realized. The liver is the main site of iron storage and the liver iron concentration (LIC) is closely correlated with total iron stores in patients with secondary hemosideroses and genetic hemochromatosis. Magnetic resonance imaging is now the gold standard method for LIC estimation and monitoring in non-renal patients. Studies of LIC in hemodialysis patients by quantitative magnetic resonance imaging and magnetic susceptometry have demonstrated a strong relation between the risk of iron overload and the use of intravenous (IV) iron products prescribed at doses determined by the iron biomarker cutoffs contained in current anemia management guidelines. These findings have challenged the validity of both iron biomarker cutoffs and current clinical guidelines, especially with respect to recommended IV iron doses. Three long-term observational studies have recently suggested that excessive IV iron doses may be associated with an increased risk of cardiovascular events and death in hemodialysis patients. We postulate that iatrogenic iron overload in the era of erythropoiesis-stimulating agents may silently increase complications in dialysis patients without creating frank clinical signs and symptoms. High hepcidin-25 levels were recently linked to fatal and nonfatal cardiovascular events in dialysis patients. It is therefore tempting to postulate that the main pathophysiological pathway leading to these events may involve the pleiotropic master hormone hepcidin (synergized by fibroblast growth factor 23), which regulates iron metabolism. Oxidative stress as a result of IV iron infusions and iron overload, by releasing labile non-transferrin-bound iron, might represent a 'second hit' on the vascular bed. Finally, iron deposition in the myocardium of patients with severe iron overload might also play a role in the pathogenesis of sudden death in some patients.
authors.affiliation: Division of Nephrology and Dialysis, Hôpital Privé Claude Galien, Ramsay-Générale de Santé, Quincy sous Sénart, France. rostotom@orange.fr.|Service de Néphrologie et de Dialyse, HP Claude Galien, 20 route de Boussy, Quincy sous Sénart, 91480, France. rostotom@orange.fr.
authors.forename: Guy
authors.initials: G
authors.lastname: Rostoker
authors.affiliation: Division of Nephrology and Hypertension, University of California, Irvine, CA, USA.
authors.forename: Nosratola D
authors.initials: ND
authors.lastname: Vaziri
authors.affiliation: Division of Nephrology, Hofstra North-Shore-LIJ School of Medicine, Great Neck, New York, NY, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Fishbane
mesh_terms: D006397:Hematinics / Q000008:administration & dosage; D064451:Hepcidins / Q000378:metabolism; D006801:Humans; D007049:Iatrogenic Disease; D007501:Iron / Q000009:adverse effects / Q000378:metabolism; D019190:Iron Overload / Q000503:physiopathology* / Q000517:prevention & control; D008099:Liver / Q000000981:diagnostic imaging / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D006435:Renal Dialysis / Q000009:adverse effects*
chemical_list: D006397:Hematinics; D064451:Hepcidins; D007501:Iron